熱門資訊> 正文
Xenon任命Tucker Kelly为CFO
2025-10-16 20:48
- Xenon Pharmaceuticals (NASDAQ:XENE) announced on Thursday the appointment of Tucker Kelly as Chief Financial Officer and member of the Xenon senior executive team.
- Kelly is an executive who brings extensive strategic and commercial finance expertise, both in the U.S. and internationally, that will help the company prepare for the anticipated commercialization of its lead candidate, azetukalner.
- Azetukalner is currently being studied broadly in three Phase 3 programs for the treatment of epilepsy, major depressive disorder, and bipolar depression.
- Kelly most recently served as executive vice president, CFO, and treasurer at Deciphera Pharmaceuticals, now a wholly owned subsidiary of Ono Pharmaceuticals.
More on Xenon Pharma
- Xenon Pharmaceuticals Inc. (XENE) Nav1.7 And Kv7 Programs Investor Webinar Transcript
- Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release
- Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript
- Goldman's 48 potential M&A candidates
- Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs
推薦文章
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
